Epigenetics in Hematologic Malignancies
A special issue of Epigenomes (ISSN 2075-4655).
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 5314
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hematologic malignancies that include leukemia, lymphoma, and multiple myeloma account for approximately 9% of cancers in the U.S. and Europe. Analysis of genomic data from these patients reveals that recurrent somatic mutations which affect epigenetic regulation of gene expression play a central role in the pathogenesis of lymphoid and myeloid neoplasms. These mutations may affect key proteins involved in DNA methylation, chromatin architecture, histone post-translational modification, or chromatin remodeling to alter chromatin accessibility and gene expression. Importantly, emerging therapeutic strategies target aberrant epigenetic mechanisms found in hematological malignancies to restore a more normal epigenetic state and either inhibit malignant cell growth or render these malignancies more tractable to other anti-cancer therapies such as chemotherapies or immunotherapies.
This Special Issue will focus on the role of epigenetic mechanisms in hematologic malignancies and anti-cancer therapeutics that target aberrant epigenetic mechanisms in these cancers. We welcome high-quality manuscripts (reviews, research, and technology tool articles) with a focus on the following areas:
- Epigenetic mechanisms that drive or contribute to hematologic malignancies;
- Novel epigenetic targets in hematological malignancies;
- Development or use of targeted epigenetic therapies for hematologic malignancy;
- Methods for identifying aberrant epigenetic mechanisms in hematological malignancies.
Dr. Richard L. Bennett
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epigenetics
- myeloid neoplasms
- lymphoid neoplasms
- multiple myeloma
- epigenetic therapies
- DNA methylation
- histone acetylation
- histone methylation
- chromatin remodeling
